脑色氨酸代谢与结核性脑膜炎结局:一项观察性队列研究
在印度尼西亚Hasan Sadikin医院开展的观察性队列研究,纳入33例HIV阴性确诊或很可能结核性脑膜炎患者和22例对照,检测脑脊液和血清代谢组,发现脑脊液色氨酸浓度低与生存相关(验证队列风险比0.73,95%CI 0.64-0.83,p<0.0001),且受遗传影响。
要点
- 脑脊液色氨酸浓度低与结核性脑膜炎患者生存相关,验证队列风险比0.73(95%CI 0.64-0.83,p<0.0001)。
- 脑脊液色氨酸浓度受11个遗传位点影响(p<0.00001),这些位点预测第三队列285例HIV阴性患者生存(p=0.0083)。
- 靶向色氨酸代谢的干预可能改善结核性脑膜炎结局。
核心结论
- 脑色氨酸代谢影响结核性脑膜炎结局,脑脊液色氨酸浓度受强遗传影响,可能解释结局差异,靶向色氨酸代谢的干预可能改善结局。
研究设计与样本
- 观察性队列研究,在印度尼西亚万隆Hasan Sadikin医院进行,2009年3月12日至2013年10月27日纳入33例HIV阴性确诊或很可能结核性脑膜炎患者和22例有完整临床数据的对照。
- 使用液相色谱-质谱法检测脑脊液和血清中425种代谢物。
- 在同一中心的第二队列101例患者中验证代谢物浓度与生存的关联。
- 使用全基因组单核苷酸多态性分型识别色氨酸数量性状位点,在第三队列285例患者中进行生存分析。
主要发现
- 脑脊液中检测到的351种代谢物中有250种(70%)在结核性脑膜炎患者中浓度高于对照,尤其在随访期间死亡的患者中更高。
- 血清中检测到的390种代谢物中仅5种(1%)在结核性脑膜炎患者和对照间有差异。
- 脑脊液色氨酸浓度在存活患者中低于死亡患者(9倍)和对照(31倍)。
- 低脑脊液色氨酸与生存的关联在验证队列中得到确认(风险比0.73;95%CI 0.64-0.83;p<0.0001;每减半)。
- 识别出11个预测结核性脑膜炎脑脊液色氨酸浓度的遗传位点(p<0.00001),这些位点与年龄和性别组成的预后指数预测第三队列285例HIV阴性患者的生存(p=0.0083),校正潜在混杂因素后仍显著。
关键数值与推荐
- 脑脊液色氨酸浓度每减半,生存风险比0.73(95%CI 0.64-0.83;p<0.0001)。
- 11个遗传位点预测脑脊液色氨酸浓度(p<0.00001)。
- 预后指数(包括年龄、性别和遗传位点)预测第三队列生存(p=0.0083)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunopathology contributes to the high mortality of tuberculous meningitis, but the biological pathways involved are mostly unknown. We aimed to compare cerebrospinal fluid (CSF) and serum metabolomes of patients with tuberculous meningitis with that of controls without tuberculous meningitis, and assess the link between metabolite concentrations and mortality. METHODS: In this observational cohort study at the Hasan Sadikin Hospital (Bandung, Indonesia) we measured 425 metabolites using liquid chromatography-mass spectrometry in CSF and serum from 33 HIV-negative Indonesian patients with confirmed or probable tuberculous meningitis and 22 control participants with complete clinical data between March 12, 2009, and Oct 27, 2013. Associations of metabolite concentrations with survival were validated in a second cohort of 101 patients from the same centre. Genome-wide single nucleotide polymorphism typing was used to identify tryptophan quantitative trait loci, which were used for survival analysis in a third cohort of 285 patients. FINDINGS: Concentrations of 250 (70%) of 351 metabolites detected in CSF were higher in patients with tuberculous meningitis than in controls, especially in those who died during follow-up. Only five (1%) of the 390 metobolites detected in serum differed between patients with tuberculous meningitis and controls. CSF tryptophan concentrations showed a pattern different from most other CSF metabolites; concentrations were lower in patients who survived compared with patients who died (9-times) and to controls (31-times). The association of low CSF tryptophan with patient survival was confirmed in the validation cohort (hazard ratio 0·73; 95% CI 0·64-0·83; p<0·0001; per each halving). 11 genetic loci predictive for CSF tryptophan concentrations in tuberculous meningitis were identified (p<0·00001). These quantitative trait loci predicted survival in a third cohort of 285 HIV-negative patients in a prognostic index including age and sex, also after correction for possible confounders (p=0·0083). INTERPRETATION: Cerebral tryptophan metabolism, which is known to affect Mycobacterium tuberculosis growth and CNS inflammation, is important for the outcome of tuberculous meningitis. CSF tryptophan concentrations in tuberculous meningitis are under strong genetic influence, probably contributing to the variable outcomes of tuberculous meningitis. Interventions targeting tryptophan metabolism could improve outcomes of tuberculous meningitis. FUNDING: Royal Dutch Academy of Arts and Sciences; Netherlands Foundation for Scientific Research; Radboud University; National Academy of Sciences; Ministry of Research, Technology, and Higher Education, Indonesia; European Research Council; and PEER-Health.
引用
- van Laarhoven A, Dian S, Aguirre-Gamboa R, et al. Cerebral tryptophan metabolism and outcome of tuberculous meningitis: an observational cohort study. Lancet Infect Dis. 2018. PMID: 29395996. doi:10.1016/S1473-3099(18)30053-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。